Continuing Medical Education (CME) Questions

Matched platelet transfusions in alloimmunization

To obtain credit, you should first read the journal article. After reading the article, you should be able to answer the following, related, multiplechoice questions. To complete the questions (with a minimum 75% passing score) and earn continuing medical education (CME) credit, please go to http://www.medscape.org/journal/blood. Credit cannot be obtained for tests completed on paper, although you may use the worksheet below to keep a record of your answers. You must be a registered user on http://www.medscape.org. If you are not registered on http://www.medscape.org, please click on the "Register" link on the right hand side of the website. Only one answer is correct for each question. Once you successfully answer all post-test questions you will be able to view and/or print your certificate. For questions regarding this activity, contact the accredited provider, CME@medscape.net. For technical assistance, contact CME@medscape.net. American Medical Association Physician's Recognition Award (AMA PRA) credits are accepted in the US as evidence of participation in CME activities. For further information on this award, please go to https://www.ama-assn.org. The AMA has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credits™. Through agreements that the AMA has made with agencies in some countries, AMA PRA credit may be acceptable as evidence of participation in CME activities. If you are not licensed in the US, please complete the questions online, print the AMA PRA CME credit certificate, and present it to your national medical association for review.

Marsh JC, Stanworth SJ, Pankhurst LA, Kallon D, Gilbertson AZ, Pigden C, Deary AJ, Mora AS, Brown J, Laing ES, Choo LL, Hodge R, Llewelyn CA, Harding K, Sage D, Mijovic A, Mufti GJ, Navarrete CV, Brown CJ. An epitope-based approach of HLA-matched platelets for transfusion: a noninferiority crossover randomized trial. *Blood.* 2021;137(3):310-322.

- 1. Your patient is a 69-year-old man with alloimmunized, platelet-refractory thrombocytopenia with acute myeloid leukemia. According to the randomized double-blind noninferiority crossover trial by Marsh and colleagues, which of the following statements about primary and secondary outcomes from human leukocyte antigen (HLA) epitope-matched (HEM) vs HLA standard antigen-matched (HSM) platelet transfusions is correct?
 - HEM was statistically significantly superior to HSM in the primary outcome of 1-hour posttransfusion platelet count increment (PCI)
 - \Box Transfusion requirements were significantly greater with HSM than with HEM
 - \square There were significantly more bleeding events with HSM than with HEM
 - \Box In both treatment arms, the proportion of inadequate PCI was 16%
- 2. According to the randomized double-blind noninferiority crossover trial by Marsh and colleagues, which of the following statements about HLA antibody specificity and identification of target epitopes is correct?
 - □ For every additional one epitope mismatch, the likelihood of an adequate PCI decreased by 15%
 - □ HLA antibodies were most frequently directed against HLA-A
 - □ There was no evidence of "epitope spreading"
 - \square Sera from highly sensitized patients did not have increased frequency of 166DG eplet epitopes
- 3. According to the randomized double-blind noninferiority crossover trial by Marsh and colleagues, which of the following statements about the clinical implications of outcomes of HEM vs HSM platelet transfusions is correct?
 - \square Platelet refractoriness caused by HLA alloimmunization is only a minor clinical problem
 - □ The findings suggested that epitope-matched platelets should be considered to support patients with HLA alloimmunization
 - □ Management of platelet refractoriness caused by HLA alloimmunization is easily resolved by transfusion of platelets from HLA-matched or HLA-compatible donors
 - □ An HEM approach is unlikely to identify matched products that would have been missed by searching for HSM platelets

DOI 10.1182/blood.2020010325